A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors

PURPOSE: To define maximum tolerated dose (MTD), clinical toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered in combination with docetaxel once every 21 days in patients with advanced solid tumor malignancies. EXPERIMENTAL DESIGN: Docetaxel was admi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Iyer, Gopa, Morris, Michael J., Rathkopf, Dana, Slovin, Susan F., Steers, Macaulay, Larson, Steven M., Schwartz, Lawrence H., Curley, Tracy, DeLaCruz, Anthony, Ye, Qing, Heller, Glenn, Egorin, Merrill J., Ivy, S. Percy, Rosen, Neal, Scher, Howard I., Solit, David B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3471133/
https://ncbi.nlm.nih.gov/pubmed/22124669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1789-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados